ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009

SAN DIEGO—(BUSINESS WIRE)—May. 13, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the Eighth Annual JMP SecuritiesResearch Conference on Tuesday, May 19, 2009 at 2:30 p.m. Pacific Timeat The Ritz-Carlton Hotel in San Francisco.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through June 2, 2009.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is currently developing aportfolio consisting of its five most advanced product candidatesincluding pimavanserin, which is in Phase III development forParkinson’s disease psychosis in collaboration with Biovail. In additionto pimavanserin, ACADIA has a product candidate in Phase II for chronicpain and a product candidate in Phase I for glaucoma, both incollaboration with Allergan, as well as two programs in IND-trackdevelopment. All of the product candidates in ACADIA’s pipeline emanatefrom discoveries made using its proprietary drug discovery platform.ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, InvestorRelations
Thomas H. Aasen, Vice President and ChiefFinancial Officer
(858) 558-2871